Vanda Pharmaceuticals
Clinical trials sponsored by Vanda Pharmaceuticals, explained in plain language.
Develops and commercializes therapies for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a new pill fix your body clock? phase 3 trial underway Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New topical drug could tackle stubborn toenail fungus Results expected Sep 2026 (estimated)
- New eye drops aim to soothe dry eye sufferers Results expected Sep 2026 (estimated)
- Could a schizophrenia drug tame stubborn high blood pressure? Results expected Oct 2026 (estimated)
- New pill aims to stop nausea caused by popular Weight-Loss drugs Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Promising psoriasis drug trial halted early – what now?
Disease control Stopped earlyThis study tested a drug called imsidolimab for adults with generalized pustular psoriasis (GPP), a rare and painful skin condition. The trial aimed to see if the drug is safe and works over the long term. However, the study was terminated early, so we have less information than …
Phase 3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising ichthyosis drug trial stalls after just 5 patients
Disease control Stopped earlyThis study tested a drug called imsidolimab (ANB019) in people with ichthyosis, a condition that causes dry, scaly, and red skin. The trial aimed to see if the drug could improve skin symptoms compared to a placebo. However, the study was stopped early and only enrolled 5 partici…
Phase 2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Cancer rash drug trial halted early – little known
Symptom relief Stopped earlyThis small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…
Phase 2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC